197 related articles for article (PubMed ID: 35724767)
1. Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma.
Shimizu Y; Maruyama K; Suzuki M; Kawachi H; Low SK; Oh-Hara T; Takeuchi K; Fujita N; Nagayama S; Katayama R
Cancer Lett; 2022 Sep; 543():215799. PubMed ID: 35724767
[TBL] [Abstract][Full Text] [Related]
2. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
3. Targeting
Burkart J; Owen D; Shah MH; Abdel-Misih SRZ; Roychowdhury S; Wesolowski R; Haraldsdottir S; Reeser JW; Samorodnitsky E; Smith A; Konda B
J Natl Compr Canc Netw; 2018 Sep; 16(9):1035-1040. PubMed ID: 30181415
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma.
Nakano M; Shimada Y; Matsumoto Y; Saiki T; Zhou Q; Sasaki K; Moriyama M; Yoshihara K; Natsumeda M; Kuriyama Y; Takii Y; Watanabe G; Umezu H; Okuda S; Ikeuchi T; Wakai T; Saijo Y
Clin J Gastroenterol; 2022 Apr; 15(2):413-418. PubMed ID: 35133626
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic
Capdevila J; Arqués O; Hernández Mora JR; Matito J; Caratù G; Mancuso FM; Landolfi S; Barriuso J; Jimenez-Fonseca P; Lopez Lopez C; Garcia-Carbonero R; Hernando J; Matos I; Paolo N; Hernández-Losa J; Esteller M; Martínez-Cardús A; Tabernero J; Vivancos A; Palmer HG
Clin Cancer Res; 2020 Feb; 26(4):902-909. PubMed ID: 31672771
[TBL] [Abstract][Full Text] [Related]
6. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
[TBL] [Abstract][Full Text] [Related]
7. Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistance.
Pranteda A; Piastra V; Serra M; Bernardini R; Lo Sardo F; Carpano S; Diodoro MG; Bartolazzi A; Milella M; Blandino G; Bossi G
Biomed Pharmacother; 2023 Nov; 167():115480. PubMed ID: 37713993
[TBL] [Abstract][Full Text] [Related]
8. Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors.
Falkman L; Sundin A; Skogseid B; Botling J; Bernardo Y; Wallin G; Zhang L; Welin S; Lase I; Mollazadegan K; Crona J
Ups J Med Sci; 2024; 129():. PubMed ID: 38716076
[TBL] [Abstract][Full Text] [Related]
9. Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer.
Yukimoto R; Nishida N; Hata T; Fujino S; Ogino T; Miyoshi N; Takahashi H; Uemura M; Satoh T; Hirofumi Y; Mizushima T; Doki Y; Eguchi H
Cancer Sci; 2021 Jul; 112(7):2884-2894. PubMed ID: 33934428
[TBL] [Abstract][Full Text] [Related]
10. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
Klempner SJ; Gershenhorn B; Tran P; Lee TK; Erlander MG; Gowen K; Schrock AB; Morosini D; Ross JS; Miller VA; Stephens PJ; Ou SH; Ali SM
Cancer Discov; 2016 Jun; 6(6):594-600. PubMed ID: 27048246
[TBL] [Abstract][Full Text] [Related]
11.
Tan J; Liu R; Zhu G; Umbricht CB; Xing M
Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
[TBL] [Abstract][Full Text] [Related]
12. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
[TBL] [Abstract][Full Text] [Related]
13. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
14. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Wang H; Quan H; Lou L
Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
[TBL] [Abstract][Full Text] [Related]
15. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer.
Hiraide S; Takahashi M; Yoshida Y; Yamada H; Komine K; Ishioka C
Cancer Sci; 2021 Sep; 112(9):3856-3870. PubMed ID: 34288281
[TBL] [Abstract][Full Text] [Related]
16. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
Temraz S; Mukherji D; Shamseddine A
Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
[TBL] [Abstract][Full Text] [Related]
17. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.
Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA
Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas.
Lee SM; Sung CO
Sci Rep; 2021 Mar; 11(1):6203. PubMed ID: 33737597
[TBL] [Abstract][Full Text] [Related]
19. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.
Corcoran RB; Dias-Santagata D; Bergethon K; Iafrate AJ; Settleman J; Engelman JA
Sci Signal; 2010 Nov; 3(149):ra84. PubMed ID: 21098728
[TBL] [Abstract][Full Text] [Related]
20. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells.
Sueda T; Sakai D; Kawamoto K; Konno M; Nishida N; Koseki J; Colvin H; Takahashi H; Haraguchi N; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Satoh T; Doki Y; Mori M; Ishii H
Sci Rep; 2016 Jan; 6():18949. PubMed ID: 26750638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
